Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | SNCA | P37840 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5506093 | 1.00 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL601123 | 0.89 | LMNA (0.52) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL22319095 | 0.89 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL5515828 | 0.89 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL4338933 | 0.89 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL339633 | 0.89 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL8424300 | 0.89 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL23738 | 0.88 | — | — | |
| SCHEMBL8672325 | 0.85 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL538230 | 0.85 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157442-B2 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2007-01-02 | — | — | US | disclosed |
| EP-1209166-B1 | NOVEL A-500359 DERIVATIVES | SANKYO CO (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20030171330-A1 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2003-09-11 | — | — | US | disclosed |
| US-6511965-B2 | For therapy and prophylaxis of inflammatory disorders, autoimmune diseases or septicemia | SANKYO COMPANY, LIMITED (JP) | 2003-01-28 | — | — | US | disclosed |
| US-20020161221-A1 | Ether type lipid a 1-carboxylic acid analogs | SANKYO COMPANY, LIMITED (JP) | 2002-10-31 | — | — | US | disclosed |
| EP-1209166-A1 | NOVEL A-500359 DERIVATIVES | Sankyo Company, Limited (JP) | 2002-05-29 | — | — | EP | disclosed |
| EP-1152007-A1 | ETHER TYPE LIPID A1-CARBOXYLIC ACID ANALOGUES | Sankyo Company, Limited (JP) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171330-A1 | Antibacterial compound | TLR1, MPO, O60361 | LMNA 4477/4885BLM 2245/4885PTPN1 1557/4885 |
| US-20020161221-A1 | Ether type lipid a 1-carboxylic acid analogs | MSR1, ELOVL1, FFAR1 | LMNA 2438/4885BLM 4556/4885PTPN1 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.